Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan

Post-kala-azar dermal leishmaniasis (PKDL) is a chronic, stigmatizing skin condition occurring frequently after apparent clinical cure from visceral leishmaniasis. Given an urgent need for new treatments, we conducted a phase IIa safety and immunogenicity trial of ChAd63-KH vaccine in Sudanese patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Younis, Brima M., Osman, Mohamed, Khalil, Eltahir A.G., Santoro, Francesco, Furini, Simone, Wiggins, Rebecca, Keding, Ada, Carraro, Monica, Musa, Anas E.A., Abdarahaman, Mujahid A.A., Mandefield, Laura, Bland, Martin, Aebischer, Toni, Gabe, Rhian, Layton, Alison M., Lacey, Charles J.N., Kaye, Paul M., Musa, Ahmed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261165/
https://www.ncbi.nlm.nih.gov/pubmed/33781913
http://dx.doi.org/10.1016/j.ymthe.2021.03.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261165/
https://www.ncbi.nlm.nih.gov/pubmed/33781913
http://dx.doi.org/10.1016/j.ymthe.2021.03.020

Ejemplares similares